Topical non-steroidal anti-inflammatory drugs for central serous chorioretinopathy: A systematic review and meta-analysis.
central serous chorioretinopathy
meta-analysis
non-steroidal anti-inflammatory drugs
subretinal fluid
systematic review
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
revised:
07
07
2023
received:
13
02
2023
accepted:
27
07
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
aheadofprint
Résumé
Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non-steroidal anti-inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta-analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non-randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta-analyses of comparative studies revealed a statistically significant but clinically irrelevant best-corrected visual acuity improvement of -0.04 logMAR (95% CI: -0.07 to -0.01 logMAR; p = 0.01) at 1-month follow-up, which became statistically insignificant at 3-month follow-up (-0.03 logMAR; 95% CI: -0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1-month follow-up (OR: 1.20; 95% CI: 0.81-1.76; p = 0.37) or 3-month follow-up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Alkin, Z., Osmanbasoglu, O.A., Ozkaya, A., Karatas, G. & Yazici, A.T. (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Medical Hypothesis Discovery and Innovation in Ophthalmology, 2, 96-101.
An, S.H. & Kwon, Y.H. (2016) Effect of a topical nonsteroidal anti-inflammatory agent (0.1% pranoprofen) on acute central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 254, 1489-1496.
Ayaki, M., Iwasawa, A., Soda, M., Yaguchi, S. & Koide, R. (2010) Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clinical Ophthalmology, 4, 1019-1024.
Bahadorani, S., Maclean, K., Wannamaker, K., Chu, E.R., Gresores, N., Sohn, J.-H. et al. (2019) Treatment of central serous chorioretinopathy with topical NSAIDs. Clinical Ophthalmology, 13, 1543-1548.
Borgersen, N.J., Møller-Lorentzen, T., Sørensen, T.L. & Subhi, Y. (2021) Association between C-reactive protein and polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmologica, 99, 470-477.
Brandl, C., Helbig, H. & Gamulescu, M.A. (2014) Choroidal thickness measurements during central serous chorioretinopathy treatment. International Ophthalmology, 34, 7-13.
Brinks, J., van Dijk, E.H.C., Kiełbasa, S.M., Mei, H., van der Veen, I., Peters, H.A.B. et al. (2022) The cortisol response of male and female choroidal endothelial cells: implications for central serous chorioretinopathy. The Journal of Clinical Endocrinology and Metabolism, 107, 512-524.
Brinks, J., van Dijk, E.H.C., Meijer, O.C., Schlingemann, R.O. & Boon, C.J.F. (2022) Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmologica, 100, 946-959.
Chan, L.Y., Adam, R.S. & Adam, D.N. (2016) Localized topical steroid use and central serous retinopathy. The Journal of Dermatological Treatment, 27, 425-426.
Cheung, C.M.G., Lee, W.K., Koizumi, H., Dansingani, K., Lai, T.Y.Y. & Freund, K.B. (2019) Pachychoroid disease. Eye (London, England), 33, 14-33.
Chong, C.F., Yang, D., Pham, T.Q. & Liu, H. (2012) A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Reports, 2012, bcr2012006970.
Colakoglu, A. & Cosar, B. (2017) Shallow anterior chamber in a severe case of unilateral acute central serous retinal detachment. Case Reports in Ophthalmology, 8, 326-333.
Egger, M., Davey Smith, G., Schneider, M. & Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-634.
EyeNet Magazine (2013). https://www.aao.org/eyenet/article/topical-nsaids-best-practices-safe-use (Accessed February 4, 2023).
Guidera, A.C., Luchs, J.I. & Udell, I.J. (2001) Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology, 108, 936-944.
Gunna, N.T., Parameswarappa, D.C. & Rani, P.K. (2020) Bullous central serous chorioretinopathy and retinal pigment epithelium sequelae postblunt trauma. BML Case Reports, 13, e235882.
Hersh, P.S., Rice, B.A., Baer, J.C., Wells, P.A., Lynch, S.E., McGuigan, L.J. et al. (1990) Topical nonsteroidal agents and corneal wound healing. Archives of Ophthalmology, 108, 577-583.
Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. (2003) Measuring inconsistency in meta-analyses. BMJ, 327, 557-560.
Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J. et al. (2022) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane Available from: www.training.cochrane.org/handbook
Holtz, J.K., Larsson, J.M.E., Hansen, M.S., van Dijk, E.H.C. & Subhi, Y. (2022) Pachychoroid Spectrum diseases in patients with Cushing's syndrome: a systematic review with meta-analyses. Journal of Clinical Medicine, 11, 4437.
Kido, A., Miyake, M., Tamura, H., Hiragi, S., Kimura, T., Ohtera, S. et al. (2022) Incidence of central serous chorioretinopathy (2011-2018): a nationwide population-based cohort study of Japan. The British Journal of Ophthalmology, 106, 1748-1753.
Lee, J.S., Kim, Y.H. & Park, Y.M. (2015) The toxicity of nonsteroidal anti-inflammatory eye drops against human corneal epithelial cells in vitro. Journal of Korean Medical Science, 30, 1856-1864.
Lindstrom, R. (2006) The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. International Ophthalmology Clinics, 46, 7-11.
Lotery, A., Sivaprasad, S., O'Connell, A., Harris, R.A., Culliford, L., Ellis, L. et al. (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, 395, 294-303.
Maaranen, T.H., Tuppurainen, K.T. & Mäntyjärvi, M.I. (2000) Color vision defects after central serous chorioretinopathy. Retina, 20, 633-637.
Miyake, K., Nishimura, K., Harino, S., Ota, I., Asano, S., Kondo, N. et al. (2007) The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology & Visual Science, 48, 5647-5652.
Mohd-Alif, W.M., Nur-Athirah, A., Hanapi, M.S., Tuan Jaffar, T.N. & Shatriah, I. (2022) Bilateral and multiple central serous chorioretinopathy following COVID-19 infection: a case report and literature review. Cureus, 14, e23246.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & PRISMA Group. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, b2535.
Ophthalmic NSAIDs Review (2008). https://www.medicaid.nv.gov/Downloads/provider/NVRx_DCR_20090326_Ophthalmic_NSAIDs.pdf (Accessed February 4, 2023).
Oxford Centre for Evidence-Based Medicine (2023). https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 (Accessed February 4, 2023).
Pang, C.E., Shah, V.P., Sarraf, D. & Freund, K.B. (2014) Ultra-widefield imaging with autofluorescence and indocyanine green angiography in central serous chorioretinopathy. American Journal of Ophthalmology, 158, 362-371.
Parajuli, A. & Joshi, P. (2020) Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy. BMJ Open Ophthalmology, 5, e000540.
Pecora, J.L. (1978) Ibuprofen in the treatment of central serous chorioretinopathy. Annals of Ophthalmology, 10, 1481-1483.
Pecora, J.L. (1979) Ibuprofen in the treatment of macular edema and central serous chorioretinopathy. Annals of Ophthalmology, 11, 494-495.
Putnam, C.M. & Vang, S.S. (2016) Modified photodynamic therapy treatment of central serous chorioretinopathy. Optometry and Vision Science, 93, 760-771.
Romano, M.R., Parolini, B., Allegrini, D., Michalewska, Z., Adelman, R., Bonovas, S. et al. (2020) An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European vitreoretinal society central serous chorioretinopathy study. Acta Ophthalmologica, 98, e549-e558.
Sirks, M.J., van Dijk, E.H.C., Rosenberg, N. et al. (2020) Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmologica, 100, e1522-e1532.
Spaide, R.F., Gemmy Cheung, C.M., Matsumoto, H., Kishi, S., Boon, C.J.F., van Dijk, E.H.C. et al. (2022) Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Progress in Retinal and Eye Research, 86, 100973.
Sterne, J.A., Hernán, M.A., Reeves, B.C. et al. (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919.
Subhi, Y., Bjerager, J., Boon, C.J.F. & van Dijk, E.H.C. (2022) Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data. Acta Ophthalmologica, 100, 89-95.
Subhi, Y., Krogh Nielsen, M., Molbech, C.R., Oishi, A., Singh, A., Nissen, M.H. et al. (2019) Polypoidal choroidal vasculopathy associate with diminished regulatory T cells that are polarized into a T helper 2-like phenotype. Investigative Ophthalmology & Visual Science, 60, 2583-2590.
Subhi, Y., Nielsen, M.K., Molbech, C.R., Liisborg, C., Søndergaard, H.B., Sellebjerg, F. et al. (2019) The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration. Immunity & Ageing, 16, 20.
Subhi, Y., Windfeld-Mathiasen, J., Horwitz, A. & Horwitz, H. (2023) Risk of central serous chorioretinopathy in male androgen abusers. Ophthalmology and therapy, 12, 1073-1080.
van Dijk, E.H.C. & Boon, C.J.F. (2021) Serous business: delineating the broad spectrum of diseases with subretinal fluid in the macula. Progress in Retinal and Eye Research, 84, 100955.
van Dijk, E.H.C., Feenstra, H.M.A., Bjerager, J., Grauslund, J., Boon, C.J.F. & Subhi, Y. (2022) Comparative efficacy of treatments for chronic central serous chorioretinopathy: a systematic review with network meta-analyses. Acta Ophthalmologica, 101, 140-159. Available from: https://doi.org/10.1111/aos.15263
van Dijk, E.H.C., van Rijssen, T.J., Subhi, Y. & Boon, C.J.F. (2020) Photodynamic therapy for Chorioretinal diseases: a practical approach. Ophthalmology and therapy, 9, 329-342.
van Rijssen, T.J., van Dijk, E.H.C., Yzer, S., Ohno-Matsui, K., Keunen, J.E.E., Schlingemann, R.O. et al. (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 73, 100770.
Wuarin, R., Kakkassery, V., Consigli, A., Roquelaure, D., Papanastasiou, A., Schutz, J.S. et al. (2019) Combined topical anti-inflammatory and Oral acetazolamide in the treatment of central serous chorioretinopathy. Optometry and Vision Science, 96, 500-506.
Zhang, L., Van Dijk, E.H.C., Borrelli, E., Fragiotta, S. & Breazzano, M.P. (2023) OCT and OCT angiography update: clinical application to age-related macular degeneration, central serous chorioretinopathy, macular telangiectasia, and diabetic retinopathy. Diagnostics (Basel), 13, 232.